gland pharma glp-1 manufacturing india Receptor Agonist Market Size Report, 2026-2033 Why Global Pharma Companies Prefer
Description
The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease
Symptomatic post-bariatric hypoglycemia (#PBH) affects ~8% of people who have undergone bariatric surgery
how will physicians segment these therapies
ANALYSIS METHODOLOGY For a deeper understanding of where off-label GLP-1 uses are emerging, Storyful Intelligence analyzed 29.9k mentions across conversations on X, Facebook, Reddit, and Instagram, from February 1, 2024, to March 24, 2025
